AzTrials
AzTrials

Cutaneous Squamous Cell Carcinoma (CSCC)CAREPINCT07606508

Follow-up of a French National Cohort of Patients With Cutaneous Squamous Cell Carcinoma Requiring Systemic Treatment.

An observational study of Cutaneous Squamous Cell Carcinoma (CSCC), run by University Hospital, Lille at 29 sites in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

In the context where advanced cutaneous squamous cell carcinoma (cSCC) is currently a public health issue due to its increasing incidence and where its management is rapidly evolving, it is essential to characterize and monitor changes in therapeutic strategies for patients requiring systemic treatment with… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Cutaneous Squamous Cell Carcinoma (CSCC)
What is being tested?
Systemic treatment
How many people
1,500 participants
Where
29 sitesFrance
Study dates
9 Jul 2021to 15 Jul 2036
How long will I take part?
5 Years
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients from French Centers belonging to the GCC with Cutaneous Squamous Cell Carcinoma Requiring Systemic Treatment from January 2020

Who may be able to join

  • Patients with a diagnosis of primary cutaneous squamous cell carcinoma initiating first-line systemic therapy, whether administered with curative, adjuvant, or neoadjuvant intent.
  • Male or female patients.
  • Age ≥18 years.
  • No documented objection to participation in the study.

Who cannot join

  • Patients who refuse to participate in the study or who object to the collection or processing of their personal data.
  • Initiation of systemic therapy prior to 2020.
  • Patients not requiring systemic therapy.
  • More than one line of systemic therapy at the time of inclusion.
  • Patients under legal guardianship or curatorship.
  • Individuals deprived of liberty.
  • lack of health insurance coverage.

Trial locations and contacts

29 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Laurent MORTIER, PU-PH contact

33 3 20 44 41 93

laurent.mortier@chu-lille.fr

Eve MAUBEC, PU-PH contact

33 1 48 95 70 96

eve.maubec@aphp.fr

29 sites in 1 country

France29 sites, 29 recruiting

  • CHU Dijon Bourgogne

    Amiens

    Jean-Philippe ARNAULT, 33 3 22 45 58 43, arnault.jean-philippe@chu-amiens.fr

    Jean-Philippe ARNAULT

    Not yet recruiting

  • Centre Hospitalier Régional d'Orléans

    Annecy

    Julie DE QUATREBARBES, 33 4 50 63 68 63, jdequatrebarbes@ch-annecygenevois.fr

    Jule DE QUATREBARBES

    Recruiting

  • CHRU Besançon

    Besançon

    François AUBIN, 33 3 81 66 81 66, faubin@chu-besancon.fr

    François AUBIN

    Recruiting

  • Centre Hospitalier de Blois

    Blois

    Guido BENS, 33 2 54 55 66 33, bensgui@ch-blois.fr

    Guido Bens

    Recruiting

  • Hôpital Avicenne

    Bobigny

    Eve MAUBEC, 33 1 48 95 70 96, eve.maubec@aphp.fr

    Eve Maubec

    Recruiting

  • Hôpital Saint André,

    Bordeaux

    Marie BEYLOT-BARRY, 33 5 57 82 25 00, marie.beylot-barry@chu-bordeaux.fr

    Marie BEYLOT-BARRY

    Recruiting

  • Hôpital Ambroise Paré

    Boulogne-Billancourt

    Elisa FUNCK BRENTANO, 33 1 49 09 56 73, elisa.funck-brentano@aphp.fr

    Elisa FUNCK-BRENTANO

    Recruiting

  • CHU de Caen

    Caen

    Anne DOMPMARTIN, 33 2 31 27 20 10, dompmartin-a@chu-caen.fr

    Anne DOMPMARTIN

    Not yet recruiting

  • CHRU de Tours

    Chambray-lès-Tours

    Mahtab SAMIMI, 33 247474747, mahtab.samimi@univ-tours.fr

    Mahtab SAMIMI

    Recruiting

  • CHU Estaing

    Clermont-Ferrand

    Sandrine MANSARD, 33 4 73 75 05 50, smansard@chu-clermont-ferrand.fr

    Sandrine MANSARD

    Recruiting

  • CHU Henri Mondor

    Créteil

    Ouidad ZEHOU, 33 3 149814513, ouidad.zehou@aphp.fr

    Ouidad ZEHOU

    Recruiting

  • CHU Dijon Bourgogne

    Dijon

    Géraldine JEUDY, 33 3 80 29 33 36, geraldine.jeudy@chu-dijon.fr

    Géraldine Jeudy

    Recruiting

  • Centre Hospitalier Le Mans

    Le Mans

    Nathalie BENETON, +33 2 43 43 43 43, nbeneton@ch-lemans.fr

    Nathalie BENETON

    Recruiting

  • CHU Lille

    Lille

    Laurent MORTIER, 33 3 20 44 41 93, laurent.mortier@chu-lille.fr

    Laurent MORTIER

    Recruiting

  • CHU Dijon Bourgogne

    Lyon

    Mona AMINI-ADLE, 33 4 78 78 59 66, mona.amini-adle@lyon.unicancer.fr

    Mona AMINI ADLE

    Recruiting

  • Hôpital de la Timone

    Marseille

    Caroline GAUDY - MARQUESTE, 33 4 91 38 57 80, Caroline.Gaudy@mail.ap-hm.fr

    Caroline GAUDY - MARQUESTE

    Recruiting

  • CHRU Montpellier Hôpital Saint Eloi

    Montpellier

    Candice Lesage, 33 4 67 33 69 06, candice-lesage@chu-montpellier.fr

    Candice Lasage

    Recruiting

  • Hôpital St Eloi

    Montpellier

    Olivier DEREURE, 33 4 67 33 69 06, o-dereure@chu-montpellier.fr

    Olivier DEREURE

    Not yet recruiting

  • CHU Nantes

    Nantes

    Gaëlle QUEREUX, 33 2 40 08 33 33, gaelle.quereux@chu-nantes.fr

    Gaëlle QUEREUX

    Recruiting

  • CHU de Nice

    Nice

    Henri Montaudié, 33 4 92 03 60 83, montaudie.h@chu-nice.fr

    Henri Montaudié

    Recruiting

  • Centre Hospitalier Régional d'Orléans

    Orléans

    Antoine MARCHAND, 33 2 38 51 44 44, antoine.marchand@chu-orleans.fr

    Antoine MARCHAND

    Recruiting

  • Hôpital Bichat-Claude-Bernard

    Paris

    Florence BRUNET-POSSENTI, 33 1 40 25 80 80, florence.brunet-possenti@aphp.fr

    Florence Brunet-Possenti

    Recruiting

  • Hôpital Cochin-Port Royal

    Paris

    Sarah GUEGAN, 33 1 58 41 18 06, sarah.guegan@aphp.fr

    Sarah GUEGAN

    Not yet recruiting

  • Hôpital St Louis

    Paris

    Céleste Lebbe, +33-1-42-49-93-92, Celeste.lebbe@aphp.fr

    Céleste Lebbe

    Recruiting

  • CHU Charles Nicolle

    Rouen

    Anne-Bénédicte DUVAL-MODESTE, 33 2 32 88 81 41, anne-benedicte.duval-modeste@chu-rouen.fr

    Anne-Bénedicte Duval-Modeste

    Recruiting

  • Institut de Cancérologie de l'Ouest

    Saint-Herblain

    Lucie PEUVREL, 33 2 40 67 98 93, lucie.peuvrel@ico.unicancer.fr

    Lucie PEUVREL

    Recruiting

  • HIA Sainte Anne

    Toulon

    Enrolling by invitation

  • Centre Hospitalier de Valence

    Valence

    Florent GRANGE, 33 4 75 75 75 49, fgrange@ch-valence.fr

    Florent GRANGE

    Recruiting

  • CHRU de Nancy

    Vandœuvre-lès-Nancy

    Florence GRANEL-BROCARD, 33 3 83 15 71 46, f.granel-brocard@chu-nancy.fr

    Florence GRANEL-BROCARD

    Recruiting

Other trials in France

About this study

In the context where advanced cutaneous squamous cell carcinoma (cSCC) is currently a public health issue due to its increasing incidence and where its management is rapidly evolving, it is essential to characterize and monitor changes in therapeutic strategies for patients requiring systemic treatment with adjuvant/neoadjuvant or curative setting.

The overall objective of this study is to describe the long-term, real-life management of patients with cSCC requiring systemic therapy, including their clinical characteristics as well as treatment effectiveness and safety. To achieve this aim, the project is based on the establishment of a French national database of patients with cSCC receiving systemic therapy. This is a non-interventional multicenter study involving approximately 30 centers from the French Cutaneous Oncology Group (GCC), including a retrospective phase (from January 2020 for initiation of first-line systemic therapy) followed by a prospective phase.

Time perspective is Retrospective and Prospective

Being tested
Systemic treatment
Keywords
Cutaneous Squamous Cell Carcinoma (CSCC), skin, Adjuvant Treatment, Neoadjuvant treatment, Curative treament

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Systemic treatmentDrug

    Adjuvant Treatment Neoadjuvant Treatment Curative Treatment

Study groups in NCT07606508
Study groupRoleWhat they receive
Patients with Cutaneous Squamous Cell Carcinoma Requiring Systemic TreatmentNot described
Receives: Drug: Systemic treatment

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Frequency and duration of treatments according to the line therapy and treatment intent (curative, adjuvant, or neoadjuvant), and their evolution over time.

    Measured: Long term follow-up, Average of 5 years, Duration of the project not defined

Secondary outcomes (3)

  1. Description in real-life of treatment effectiveness according to treatment type, including response rate, time to response, progression-free survival, overall survival, duration of response, and the incidence of severe toxicities.

    Measured: Long term follow-up, Average of 5 years, duration of the project not defined

  2. Identification of novel prognostic factors or predictive factors of treatment response and/or toxicity.

    Measured: Long term follow-up, Average of 5 years, duration of the project not defined

  3. Characterization of baseline patient features

    including demographics, risk factors, comorbidities, clinical presentation and histopatological characteristics

    Measured: At the moment of Cutaneous Squamous Cell Carcinoma Diagnosis, until Day 1 of therapy line

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 May 2026
  2. Study start9 Jul 2021
  3. Primary completion15 Jul 2036 (estimated)
  4. Study completion15 Jul 2036 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Other
Enrolment
1,500 participants (estimated)
Target duration
5 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT07606508
Sponsor's protocol ID
2020_81
Other IDs
IDRCB
Acronym
CAREPI
Status last verified
May 2026
First submitted
11 May 2026
Last updated
26 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in